Biogazelle HTPathwaySeq and HTTargetSeq
Belgian CRO Biogazelle has launhced HTPathwaySeq and HTTargetSeq RNA sequencing and data-analysis services. HTPathwaySeq generates in-depth information on drug mode of action, highlights molecular similarities between compounds, and reveals potential compound-induced toxicities, all of which help provide critical data for candidate prioritization in drug development. HTTargetSeq supports the development of RNA-targeting oligonucleotides such as short interfering RNAs (siRNA) and antisense oligonucleotides (ASO). The service accurately identifies off-target genes, which the company noted is important for the anticipation of safety issues and potential repurposing of off-target genes as novel therapeutic targets. Both services are performed directly on cell lysates from 96-well culture plates, and data interpretation results are shared through Savana, Biogazelle’s proprietary visualization app.